Who may be appropriate for AURYXIA?
There are many options when it comes to prescribing a treatment for hyperphosphatemia.
AURYXIA is contraindicated in patients with iron overload syndromes (e.g., hemochromatosis).
Patients to consider for AURYXIA
Adults with CKD receiving dialysis in need of phosphorus control who1*:
- Are above the target phosphorus range per clinical guidance or
- May be non-compliant with their current binder or
- Prefer non-chewable tablets or
- Have concerns about calcium-based binders or
- Are on in-center or home dialysis
*CKD=chronic kidney disease.
Not an actual patient.
“When I see a patient who has uncontrolled phosphorus, I will typically take the opportunity of starting the patient on AURYXIA.”— Constance Nicastro-Bowman, CNP Nurse PractitionerHear from your peers on why they prescribe AURYXIA
See how AURYXIA helped patients reach their target goals
AURYXIA helped patients reach and stay in the range of 3.5-5.5 mg/dL during a 56-week trial1,2
Patients had a mean serum phosphorus level of 7.41 mg/dL at baseline and 4.88 mg/dL at Week 56.1
You may also be interested in:
A multicenter, randomized, open-label, Phase III trial evaluated the safety and efficacy of AURYXIA as a phosphate binder in controlling serum phosphorus levels in adult patients with CKD on hemodialysis and peritoneal dialysis over 56 weeks. Eligible patients were on dialysis for ≥3 months before screening, were prescribed 3 to 18 pills/day of commercially available phosphate binder, and had serum ferritin <1000 ng/mL, serum TSAT <50%, and serum phosphorus ≥2.5 and ≤8.0 mg/dL at the screening visit. Patients who were intolerant to calcium acetate and sevelamer carbonate were not included in the trial.
The safety and efficacy of AURYXIA was studied in the 52-week Active Control Period (AURYXIA n=292, Active Control n=149). At the final Active Control Period visit, AURYXIA patients were re-randomized to either continue AURYXIA treatment or receive placebo as part of the Placebo-Controlled Period (AURYXIA n=96, placebo n=96). The primary endpoint of the pivotal trial was the change in serum phosphorus from baseline (Week 52) to Week 56 between AURYXIA and placebo in the 4-week Placebo-Controlled Period.
CKD=chronic kidney disease; TSAT=transferrin saturation; Active Control=sevelamer carbonate and/or calcium acetate.